Uromigos
@Uromigos
Followers
7K
Following
575
Media
528
Statuses
2K
The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Joined February 2017
A summary of the ADC session at #UromigosLive24 with @apolo_andrea @shilpaonc @PGrivasMDPhD @tompowles1 & @kalasri3
3
47
122
🧵#UromigosLive #ProstateCancer Poll: Emerging therapeutic approaches for the treatment of mHSPC ‼️👇POLLS TO FOLLOW‼️ (1/3) 👇
6
42
85
Paper of the month: @JoshMeeks develops 5 subgroups based on RNA signatures to predict response a PD(L)1 in urothelial cancer (figure bellow). Multiple mechanisms of response/resistant creates a complex picture which Josh simplifies .
2
36
86
🧵#UromigosLive #ProstateCancer Poll: You've seen data for mHSPC doublet trials👇 from #CHAARTED #Stampede #Latitude #TITAN #ARCHES #ENZAMET and triplet trials 👇from #PEACE1 #ARASENS. No trial compared ADT + ARAT versus ADT + ARAT + Docetaxel. ‼️POLLS TO FOLLOW‼️ (1/6)
6
57
83
Prostate cancer poster highlights #asco22 . Which patients benefit from docetaxel chemotherapy @ChrisSweens1
5
23
83
@brian_rini and @tompowles1 have launched a new website, featuring podcasts, videos, Uromigos Live annual meeting material and much more! Visit soon for #GU23 content. @montypal @shilpaonc @PGrivasMDPhD @neerajaiims @drenriquegrande @DrChoueiri
2
17
79
🧵#UromigosLive #ProstateCancer: Most successful strategies for developing anticancer combination Rx commonly adhere to the following👉1⃣ Distinct MOA 2⃣ Significant single agent activity3⃣ Non-overlapping toxicities ➡️Ex. BEP for germ cell tumors. mHSPC following the example‼️
1
34
80
ASCO23 GU highlights. What’s changed in prostate (PARPi, PEACE1, ICECAP, AI pathology) - bladder (THOR and VESPER) - renal (CONTACT3) please give us feedback - many thanks @brian_rini
4
12
78
1st line bladder cancer, what just happened? #nashvillelive Was nivo/cis data expected? Who shouldn’t get EV pembro? How much does maintenance avelumab help? What next now EV/pembro is standard treatment? @DrRosenbergMSK @MattGalsky @shilpaonc 👉
1
27
78
#UromigosLive 2023 will feature a 'Rising Stars' session this year. Promoting the next generation of GU Oncology research is part of our core mission.
3
22
72
Pembrolizumab is approved in BCG refractory NMIBC. A new chapter begins for these patients. These drugs seem to work best in earlier disease. Randomised trials will be needed to confirm the benifit. We also need biomarkers as <50% benifit.
4
44
66
#ESMO Clinical Practice Guidelines eUpdates just released for immune and targeted therapy in bladder cancer #urothelialcancer 👉 #blcsm @myESMO #OncoAlert #niioncologii
1
41
66
2nd attempt a showing A prize winning prostate cancer poster @neerajaiims discussed by @Daniel_J_George
2
17
59
The Cancer Immunity Cycle has been updated! Listen to the details here as Ira Mellman breaks down this update.
0
25
57
APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to @neerajaiims for help with the tweet. #APCCC2024 @OncoAlert .
2
24
55
🧵#UromigosLive #KidneyCancer Poll 1: You've seen the data for adjuvant therapy at #ESMO22 from #CM914, #IMmotion010 & #PROSPER, summarized against #KN564 below. No @myESMO data was +, but updated data from #KN564 in @TheLancetOncol continues to hold. ‼️POLLS TO FOLLOW‼️ (1/6)
1
33
56
Last golden ticket #UromigosLive is up for grabs.The best new photo with the Uromigos name in a selfie wins-a scribbled bit of paper is ok. It’s for developing doctors but anyone can enter & pick a person of their choice,so even @ChrisSweens1 @DrChoueiri @Silke_Gillessen can win
4
9
54
📢#UromigosLive #KidneyCancer.Excellent discussion on perioperative strategies in #RCC w @TiansterZhang @tompowles1 @brian_rini @montypal #AxelBex #DavidMcDermot!.🎖️A round of applause to @TiansterZhang for winning the Golden Kidney prize with her future adjuvant study design!
0
19
49
1/6 The NIAGRA perioperative durvalumab trial in muscle invasive bladder cancer was positive for EFS and OS #UromigosLive24. Shortcomings and future data also discussed. 84% thought this was the new standard of care. There are two other similar trials with PD-1 inhibitors
1
27
54
Uromigos Rising Star series kicks off with Renee Saliby discussing her work on RNA signatures predicting response to therapy in advanced renal cancer @ReneeSaliby @DrChoueiri
2
12
54
1/2 Here’s our updated advanced urothelial cancer Uromigos Score (20 experts from around the world). It’s designed to give clinical strength/granularity to guidlines (which often give a list of equal options). Thanks to those that took part (on the 2nd slide). As things change,
4
19
54
50,000 uromigos listens in our first year. Thanks to all those who have taken part and a huge thanks to the audience who have persisted with us despite all the shortcomings.
0
11
53
🧵#UromigosLive #KidneyCancer Poll 2: #COSMIC313 was presented at #ESMO22 by @DrChoueiri. HR was 0.73 for PFS (met primary EP); no OS data presented at @myESMO. Triplet w 3% CR, 43% RR. @brian_rini assembled this table stacking up data in I/P risk pts. ‼️POLLS TO FOLLOW‼️ (1/8)
3
23
53
Adjuvant nivolumab in bladder cancer for everyone, some or none? #UromigosLive @PGrivasMDPhD
3
12
51
#UromigosLive meeting Livestream (all times Eastern US time):. *Friday, Sept 30 - Bladder Cancer: 2-3PM.*Saturday, Oct 1 - Prostate Cancer: 11AM-noon . - Renal Cancer: 3-4PM. Livestream link/detailed agenda to follow!
1
21
52
Imvigor130 (front line bladder chemo+atezo) is positive for PFS, with OS trending positive. PFS has not been easy to achieve previously in bladder. I have been more confident about OS, which will get there in time. A new standard of care I suspect. Tom
1
21
51
We’re having an interactive uromigos meeting in Nashville 30 Sept-1st Oct @DrRanaMcKay @MattGalsky @neerajaiims @DrRosenbergMSK @Prof_Nick_James @montypal @TiansterZhang @shilpaonc @PGrivasMDPhD @Daniel_J_George @kalasri3 details in the podcast
0
24
51
UROMIGOS unsung poster hero - prostate cancer. Outcomes comparing continuous vs intermittent ADT by 7 month PSA response. ‘It looks like you need to keep your foot on the break’ @ChrisSweens1 #GU25
1
14
51
THANK YOU for your support and over 400,000 listens! .ASCO GU podcasts:. 🥸Prostate- TALAPRO @neerajaiims, ARPI discussion @TDorffOnc .🙃Bladder - FGF3 inhibitor @IyerGopa, NIAGRA pathCR @MattGalsky, neoadj DV/PD1.😃RCC - ARCUS HIF @DrChoueiri, CM214 KIM-1 data @VincentWenxinXu,
0
16
51
Rechallange with pembrolizumab in UC in those patients who complete 2 yrs of therapy or stop due to CR is associated with responses. A highly selected population. What does this mean in the adjuvant therapy setting? #nashvillelive @koshkin85 #ESMO2023
1
16
48
ctDNA data in RCC. Detectable and informative. More work needed, but a liquid biomarker is appealing. @tompowles1 @brian_rini #ctDNA
1
5
48
We love our Rising Stars! Terrific study designs all around. Save this tweet - you are probably sure to see some of these trials advance to P3 in the future, wouldn't you say @PGrivasMDPhD @morr316 @TDorffOnc?
That's a wrap on the fantastic rising stars panel at #UromigosLive! Give it up for @PBarataMD, @bergsa83, @anis_a_hamid, @AmandaNizamMD, and @DrKarineTawagi!
0
21
48
We have 2 winners for the last Uromigos golden ticket. @ReneeSaliby (surfing) & @EbrahimiHedyeh (Hollywood) winning. Excellence from @PGrivasMDPhD + friends(beach), @montypal in the pub @shilpaonc (& puppy) @DrDanielHeng (forest) @zapatalaguadomd listening to @drenriquegrande
4
17
49
The positive CHMP decision for axitinib and pembrolizumab in front line renal cancer is great news for EU patients. High response rates (60%), long PFS (>15 months) and a 47% reduction in the risk of death, irrespective of risk group, makes it really attractive. Tom.
0
15
47
Adjuvant therapy in renal cancer. Where we are now and what’s next? @montypal #UromigosLive #nashville22
1
14
47
The 3rd Annual #UromigosLive conference will be in Nashville September 27/28. Amazing faculty including @PGrivasMDPhD @MattGalsky @shilpaonc @DrChoueiri @TDorffOnc @HHammersMD @AlbigesL @TiansterZhang @morr316 and more!! Rising Stars, Uromigos Cup and some surprises! @MdMashup
2
22
48
The #UromigosLive #BladderCancer Poll 3: We have come a long way in drug dev in #BladderCancer since the 1st approval of IO in 2016!.Tx paradigm in 2022 (1/3)👇.@tompowles1 @DrRosenbergMSK @brian_rini
2
21
47
Our 2nd golden ticket winner for Uromigos Nashville’23 is Vadim Koshkin @koshkin85 We are having a livestream debate on the treatment of 1st line bladder cancer (Nov 3rd) as Vadim suggested. Discussion of ESMO23 data. @DrRosenbergMSK @shilpaonc @MattGalsky @PGrivasMDPhD
4
13
45
It is great to see years of kidney cancer development has resulted in overall survival being used as the primary endpoint and improvements achieved - unequivocal clinical benefit! Well done to all who have contributed over the many years.
0
13
44
Our prostate cancer debate with Rana McKay and Kim Chi covers 1st line doublet vs triplet therapy. This video is a quick summary - the podcast has the detail.
1
11
44
Thinking about a specific moment during the #UromigosLive24 live panel sessions? . Find the first #bladdercancer session on peri-operative therapy broken down into four parts at the link below, with more to come. 👉
0
19
44
@tompowles1 and @brian_rini are looking forward to the @Uromigos session at the World Conference on GU Cancers next weekend for a special session on the impact of recent data in GU cancers on community practice.
3
14
45
A fantastic meeting in Madrid. Imvigor130 was debated by the Spanish group who made such a huge contribution. Consensus on the significance of the results was elusive. Most seem keen to wait for significant OS before making changes. I’m inclined to agree. #sogug1 #simposioSOGUG
0
4
41
We’re doing it again. Uromigos Live 2023 in Nashville November 3-4. Live sessions, videos and podcasts A #uromigoscup . Highlights from ESMO. New perspectives. Golden tickets for rising stars. Happy to hear your ideas
1
9
44
#UromigosLive Day 2 .#ProstateCancer session: The Changing Landscape of mHSPC Treatment 👇(1/2)
2
18
43
@Silke_Gillessen and @ProfKHerrman discuss predictive characteristics associated with response from the VISION study. #ASCO2023. @morr316
0
6
42
Estamos iniciando una serie de podcasts en español, Las Tres Amigas con Begoña, Cristina y Elena @Ecastromarcos @crisuarez08 @begopval. Esperamos que os gusten. Aquí está el enlace al primer podcast. @brian_rini @drenriquegrande @tompowles1 @cdanicas
0
9
43
Press release states this first line maintenance study achieves OS in the ITT population (cisplatin eligable and inelgable) and is therefore distinct from front line atezo/pembro which are currently limited to biomarker positive cisplatin ineligable.
1
17
42
Romain Banchereau joins us to discuss his @Cancer_Cell manuscript on molecular subtypes of urothelial cancer and implications for response to checkpoint inhibition.
1
11
39
#ESMO23 PSMAFore Ph3 trial results👉 Pluvicto (Lu177) shows ⬆️rPFS vs ARPI change in taxane-naïve mCRPC #prostatecancer (Pts with any PSMA neg lesions on PSMA PET were excluded)👉57% reduction in risk of progression 👇@Uromigos #UromigosLive Find 5 Polls below 👇 (1/6)
1
22
36
Kicking off the @Uromigos Canary Islands tour. Podcasts, videos, swimming race and more coming soon! @OncoAlert
1
14
41
🧵#UromigosLive #BladderCancer Poll 1: .Adjuvant high-risk muscle-invasive UC.IMVigor010- atezo NEG for DFS & OS.CM274 nivo met DFS endpoint in ITT & PD-L1 >/=1% NO OS data--Poll to follow (1/3)
1
24
40
With this coming ASCO and emergence of many active therapies for GU cancers, I personally will be less inclined to be comfortable with phase 3 trials calling success with only a PFS benefit without a QoL benefit or proven surrogacy for OS. (Chris) @ChrisSweens1.
1
6
38
Bladder cancer Asco 2019: maintenance pembrolizumab after front line chemo delaying PFS. The first PFS positive immune therapy study. OS awaited. Big success. Also bevacizumab with chemo hitting PFS but not OS. Huge effort. Great investigator led studies from Gasky/Rosenberg.
0
12
37
The uromigos podcast tour had 16 stops in 5 continents. Chris Sweeneys discussion on biomarkers in Prostate cancer was the most popular.
0
8
37
Check out our APCCC podcasts with Jason Efstathiou and Piet Ost discuss the data for and against adjuvant radiotherapy.
2
10
37
We think this might be worth a quick listen. Urothelial Cancer Highlights from ASCO GU 2020
3
14
36
There are not too many ways of getting tickets to #UromigosLive2024 in September in Nashville, but winning the @uromigos darts 🎯 🎯 🎯 competition at the annual party is one. Dr Ovidio Calvo 🇪🇸 threw magic darts (only 1 actually) & cleaned up. Welcome to Nashville. #worlddarts
1
8
38
Golden tickets 🎟️ for the Uromigos Nashville 23 meeting available. It’s for junior faculty and includes accommodation🏨 , ✈️ social events 🎺 etc. Send us ideas for a podcast + presenter. Reply to this tweet or site.
15
15
38
#UromigosLive24 will discuss IO after IO in RCC. Despite negative trials this practice persists. Do we need a post adjuvant trial of IO? How long after adjuvant pembro would you rechallenge? Do patients get only one good shot at IO?
1
13
36
In the 2nd podcast in the Rising Star series. Scott Haake described his work on ctDNA and methylation signatures in renal cancer. Please send us your nomination for the rising star series. We’re looking for 5 more in 2022. @DrScottHaake @KimrynRathmell
0
14
36
A late entry for the final UROMIGOS golden ticket #nashvillelive from RCC legend @DrDanielHeng It’s from a Canadian rain forest apparently. He’s not surfing, and I’m not sure about the predictive nature of his classification, but surely he is in with a chance @montypal
2
7
37
Team 🇺🇸 USA 🇺🇸 winning the Uromigos cup 🏆🏆🏆👍👍👍against Japan. Thanks to all the teams Mexico 🇲🇽 France 🇫🇷 Germany 🇩🇪 Netherlands 🇳🇱 and Canada 🇨🇦 #uromigosLive
2
6
36
La segunda edicion de Temas de Actualidad en cancer GU en las islas canarias comienza hoy @uro_oncologist @g_develasco @brian_rini @tompowles1
2
7
35
Post @myESMO data by @AndreaNecchi on SunRise-1 TAR-200 in BCG-unresponsive NMIBC, CR 77! Impressive DoR. Poll to follow (1/2)
1
17
36
Great, very well done study, now the discussions will begin which AR targeted substance and which combinations should be added to ADT. It will be interesting to see the biological data of this study!
1
7
36
The standard of care for papillary RCC has evolved over the last few years. We discussed this at #UromigosLive24 with @tompowles1, @AlbigesL, @HHammersMD and David McDermott. SUNNIFORECAST was presented at #ESMO24.
1
19
35
10,000 views for uromigos podcasts. Unexpected when one considers the quality of chairing by @tompowles1 @brian_rini and regular interruptions/poor sound quality. Some great presenters though. @montypal @ChrisSweens1 @DrChoueiri @ERPlimackMD @AlbigesL @kalasri3 @Silke_Gillessen
1
7
36
Dr Grivas @PGrivasMDPhD wiped the floor with me in a debate of PD-L1 vs 2nd generation biomarkers in Bladder Ca (TMB CD8 etc). TMB got a particularly rough ride. It appears PD-L1 will stand the test of time, probably in combination with other biomarkers (CD8) to enrich response.
2
0
35
⭐ Our latest episode with @DrRosenbergMSK focuses on the phase 3 TROPiCS-04 study, which was recently presented at ESMO Asia 2024. Tune in to learn about the study's efficacy and toxicity signals. 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
1
11
35
Sequential tissue analysis after neoadjuvant atezolizumab shows dynamic changes with therapy. Baseline activated T cells predict response. Up regulation of fibroblast (FAP) and cell cycle genes predict resistance. TMB and PD-L1 seem less relevant
2
17
33
UROMIGOS Unsung Poster Award. @crisuarez08 presents the study of Pembro-based IO doublets in IO-refractory RCC. Some activity to the CTLA-4 arm. Novel approaches in this space are needed.
2
10
36
Nick Vogelzang gives an overview of developments in kidney cancer from the start and key moments in his career as part of the uromigos Legend weekly series.
0
9
35
9/21 (43%) pathological complete response rates for durvalumab and tremelimumab in operable urothelial bladder cancer at ASCO2019#4551. Single agent PD-(L)1 inhibitor response rates are 30-40% (~same as chemo). Immune combos could be even better. IO looks most active here.
0
9
33
. Amazing really - nothing for 40 years - then immune checkpoint inhibitors, FGFR and EV (ADCs) all in 5 years. I think, for the first time, most patients won’t be having chemotherapy as standard of care in the near future.
1
7
34
The new EAU guidelines recommending axitinib/pembrolizumab as front line therapy for metastatic RCC irrespective of IMDC risk group. Ipilimumab/nivolumab continues to be recommended in intermediate and poor risk pateints. So it’s PD-1 + VEGF or CTLA-4.
2
13
33
⭐ Professor @_ShankarSiva of @PeterMacCC joins the show to discuss the emerging role of stereotactic body radiotherapy in primary and metastatic RCC tumors. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple
0
10
34
An unanswered question in these guidelines is how to chose between Ipi/nivo and axi/pembro.
New renal cancer guidelines recommending axitinib and pembrolizumab irrespective of IMDC risk group.
2
9
33
We have a 2nd golden ticket award winner @AmandaNizamMD for Nashville’22 . Amanda highlights ongoing uncertainty around the agenda and faculty. @brian_rini assures us the social events are maturing well.
0
8
33
⭐ Review some of the top highlights from @ASCO #GU25 in the prostate, bladder, and kidney cancer fields with returning guest @Silke_Gillessen. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
1
19
34
@BraunMDPhD talks about elegant single cell RNAseq data from the HCRN nivo RCC trial. #ASCO23
0
15
33
In Episode 386 the Uromigos will be discussing which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD). Join here:
0
13
33
Thanks to everyone who listens and especially the >100 guests who made these happen. @Silke_Gillessen @ChrisSweens1 @AlbigesL @kalasri3 David and Christina.
1
3
33
😱 Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by @tompowles1, @apolo_andrea, @PGrivasMDPhD, @shilpaonc, and @kalasri3. 🔬 Learn about a new study from Dr. Yohann Loriot of @GustaveRoussy on BT8009, HER3, and
0
17
32